News and Press Releases

PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes

Investment to enable progression of pipeline of novel degrader assets through pre-clinical development and support further development of GlueSEEKER platform Led by Parkwalk Advisors alongside existing investors BGF, Dr Jonathan...

Category: Drug Discovery, Other, Pharmaceutical
Posted: September 10, 2024

PhoreMost Ltd, Building B580, Room 2011, Babraham Research Campus, Babraham, Cambridge, CB22 3AT, United Kingdom

PhoreMost introduces GlueSEEKER platform for discovery of molecular glue degraders

New drug discovery platform integrates computational approaches with molecular biology for development of novel degrader therapeutics 21 May 2024 -- Cambridge, UK -- PhoreMost, a leading UK biopharmaceutical company unlocking...

Category: Biotechnology, Drug Discovery, Pharmaceutical
Posted: May 21, 2024

PhoreMost Ltd, Building B580, Room 2011, Babraham Research Campus, Babraham, Cambridge, CB22 3AT, United Kingdom